RECRUITINGOBSERVATIONAL

Cognitive Assessment Tools for Huntington's Disease.

Cognitive Assessment Tools for Individuals With Huntington's Disease.

About This Trial

The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Males and females aged 30-65 (inclusive) at the time of signing the willing to sign a consent form form. 2. Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40. 3. A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4. 4. Vision and hearing sufficient for compliance with tests. 5. On a stable dose of medications for 30 days prior to the time of signing the willing to sign a consent form form. Who Should NOT Join This Trial: 1. Age of symptom onset less than 19 years old or greater than 60 years old. 2. Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant. 3. Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune conditions (where your immune system attacks your own body)s, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure). 4. Subjects who are pregnant or breast feeding 5. Subjects with a history of a learning disability. 6. Subjects who are unable to provide consent. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Males and females aged 30-65 (inclusive) at the time of signing the informed consent form. 2. Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40. 3. A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4. 4. Vision and hearing sufficient for compliance with tests. 5. On a stable dose of medications for 30 days prior to the time of signing the informed consent form. Exclusion Criteria: 1. Age of symptom onset less than 19 years old or greater than 60 years old. 2. Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant. 3. Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure). 4. Subjects who are pregnant or breast feeding 5. Subjects with a history of a learning disability. 6. Subjects who are unable to provide consent.

Treatments Being Tested

BEHAVIORAL

Assessments

A standardized assessment battery will be administered. It will consist of cognitive, functional and motor assessments.

Locations (1)

The Ohio State University Wexner Medical Center

Columbus, Ohio, United States